Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 2 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found